WO1995033048A3 - P2x receptors (purinoceptor family) - Google Patents

P2x receptors (purinoceptor family) Download PDF

Info

Publication number
WO1995033048A3
WO1995033048A3 PCT/EP1995/001968 EP9501968W WO9533048A3 WO 1995033048 A3 WO1995033048 A3 WO 1995033048A3 EP 9501968 W EP9501968 W EP 9501968W WO 9533048 A3 WO9533048 A3 WO 9533048A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
receptors
diseases
atp
prepared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1995/001968
Other languages
French (fr)
Other versions
WO1995033048A2 (en
Inventor
Soledad Valera
Gary Nutter Buell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9410664A external-priority patent/GB9410664D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to AU25665/95A priority Critical patent/AU2566595A/en
Priority to EP95920076A priority patent/EP0760850A1/en
Priority to JP8500271A priority patent/JPH10501122A/en
Priority to US08/750,134 priority patent/US5985603A/en
Publication of WO1995033048A2 publication Critical patent/WO1995033048A2/en
Publication of WO1995033048A3 publication Critical patent/WO1995033048A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

The P2X receptor of ATP has been cloned and expressed by recombinant DNA technology, so the receptor can be prepared free from other ATP receptors. The P2X receptor enables antibodies to be prepared and is useful in screening compounds for use in a variety of diseases and conditions, including epilepsy, cognition, emesis, pain (especially migraine), asthma, peripheral vascular disease, hypertension, diseases of the immune system, irritable bowel syndrome and premature ejaculation.
PCT/EP1995/001968 1994-05-27 1995-05-24 P2x receptors (purinoceptor family) Ceased WO1995033048A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU25665/95A AU2566595A (en) 1994-05-27 1995-05-24 P-2x receptors (purinoceptor family)
EP95920076A EP0760850A1 (en) 1994-05-27 1995-05-24 P2x RECEPTORS (PURINOCEPTOR FAMILY)
JP8500271A JPH10501122A (en) 1994-05-27 1995-05-24 P ▲ 2X ▼ receptor (purinoceptor family)
US08/750,134 US5985603A (en) 1994-05-27 1995-05-24 P2x receptor DNA and protein sequence

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9410664.8 1994-05-27
GB9410664A GB9410664D0 (en) 1994-05-27 1994-05-27 DNA sequences
GBGB9502480.8A GB9502480D0 (en) 1994-05-27 1995-02-09 DNA and protein sequences
GB9502480.8 1995-02-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/363,745 Continuation US6194162B1 (en) 1994-05-27 1999-07-30 Method of screening for compounds that bind P2x receptor

Publications (2)

Publication Number Publication Date
WO1995033048A2 WO1995033048A2 (en) 1995-12-07
WO1995033048A3 true WO1995033048A3 (en) 1995-12-21

Family

ID=26304950

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/001968 Ceased WO1995033048A2 (en) 1994-05-27 1995-05-24 P2x receptors (purinoceptor family)

Country Status (5)

Country Link
US (2) US5985603A (en)
EP (1) EP0760850A1 (en)
JP (1) JPH10501122A (en)
AU (1) AU2566595A (en)
WO (1) WO1995033048A2 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0760850A1 (en) * 1994-05-27 1997-03-12 Glaxo Group Limited P2x RECEPTORS (PURINOCEPTOR FAMILY)
JP2001521372A (en) * 1996-04-30 2001-11-06 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Human P2x4 receptor splice-variant
US5856129A (en) * 1996-10-30 1999-01-05 Incyte Pharmaceuticals, Inc. DNA encoding a human purinoceptor
CA2288821C (en) * 1997-03-25 2008-10-14 Allegheny University Of The Health Sciences Modulation of human mast cell activation
JP3885177B2 (en) * 1997-03-26 2007-02-21 大塚製薬株式会社 Human gene
US6133434A (en) 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
US6228864B1 (en) 1997-10-28 2001-05-08 Vivus, Inc. Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation
US6037360A (en) * 1997-10-28 2000-03-14 Vivus, Incorporated Administration of 5-HT3 receptor antagonists to treat premature ejaculation
US5922341A (en) * 1997-10-28 1999-07-13 Vivus, Incorporated Local administration of pharmacologically active agents to treat premature ejaculation
US6242216B1 (en) 1997-11-14 2001-06-05 Abbott Laboratories Nucleic acids encoding a functional human purinoreceptor P2X2 and P2X4, and methods of production and use thereof
CA2312867A1 (en) * 1998-01-09 1999-07-15 The Trustees Of The University Of Pennsylvania Compositions and methods for use in ischemia-reperfusion and endotoxin-related tissue injury
CA2317449A1 (en) * 1998-01-16 1999-07-22 Tim Van Biesen Nucleic acids encoding a functional human purinoreceptor p2x3 and methods of production and use thereof
US6214581B1 (en) 1998-01-16 2001-04-10 Abbott Laboratories Nucleic acids encoding a functional human purinoreceptor P2X3 and P2X6, and methods of production and use thereof
WO1999055901A2 (en) * 1998-04-30 1999-11-04 Abbott Laboratories Screening assay for identifying human purinoreceptor ligands
CA2339871A1 (en) * 1998-08-20 2000-03-02 Abbott Laboratories Nucleic acids encoding a functional human purinoreceptor p2x2 and methods of producing and use thereof
AUPP991199A0 (en) 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
AU2001255448A1 (en) 2000-04-17 2001-10-30 Stephen B. Liggett Alpha-2 adrenergic receptor polymorphisms
AUPQ968700A0 (en) * 2000-08-28 2000-09-21 Intreat Pty Limited Treatment of urinary incontinence
CN101555283B (en) 2001-01-17 2012-03-21 生物权威国际有限公司 Antibodies against non-functional P2X7 receptors and their use in the diagnosis and treatment of cancer and other conditions
CA2472097A1 (en) * 2001-11-09 2003-05-15 Algos Therapeutics, Inc. Antisense modulation of purinoreceptor p2x3
AU2003215212A1 (en) * 2002-02-15 2003-09-09 Applera Corporation Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
US7211257B2 (en) 2003-02-10 2007-05-01 Rosalind Franklin University Of Medicine And Science Methods for inducing apoptosis in ovarian carcinoma cells using an anti-regeneration and tolerance factor antibody
WO2006012639A2 (en) * 2004-07-22 2006-02-02 Duska Scientific Co. Method of diagnosing, monitoring and treating pulmonary diseases
CN104644627A (en) 2004-09-14 2015-05-27 科罗拉多大学董事会 Methods for treatment with bucindolol based on genetic targeting
MX2008002014A (en) * 2005-08-15 2008-03-27 Hoffmann La Roche Piperidine and piperazine derivatives as p2x3 antagonists.
ES2596706T3 (en) * 2006-06-29 2017-01-11 F. Hoffmann-La Roche Ag Tetrazol substituted arylamides
WO2008043145A1 (en) 2006-10-10 2008-04-17 Biosceptre International Limited Hybridomas producing antibodies against non functional p2x7 receptor
US8349858B2 (en) 2007-06-21 2013-01-08 Merck Sharp & Dohme Polycyclic guanine derivatives and use thereof
JP5670192B2 (en) 2007-09-14 2015-02-18 バイオセプター・インターナショナル・リミテッド Novel P2X7 epitope
WO2009033234A1 (en) 2007-09-14 2009-03-19 Biosceptre International Limited Purinergic (p2x) receptors in extra-cellular body fluid
AU2009266430B2 (en) 2008-07-04 2014-08-14 Biosceptre International Limited Anti- P2X7 peptides and epitopes
EP3395832B1 (en) 2009-08-20 2021-11-24 Biosceptre (Aust) Pty Ltd Anti p2x7 receptor antibodies and fragments thereof
EP2516470B1 (en) 2009-12-24 2018-02-07 Biosceptre (Aust) Pty Ltd Antibodies to non-functional oligomeric p2x7 receptors
WO2012031333A1 (en) 2010-09-10 2012-03-15 Biosceptre International Limited Companion animal treatments
WO2013003895A1 (en) 2011-07-01 2013-01-10 Biosceptre International Limited Combination therapy
WO2014170343A1 (en) 2013-04-15 2014-10-23 Icm (Institut Du Cerveau Et De La Moelle Épinière) Depolarizing agents and nicotinic acetylcholine receptor modulators for treating dopaminergic-related disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0506032A1 (en) * 1991-03-28 1992-09-30 American Cyanamid Company Receptor purification method
US5360893A (en) * 1992-07-20 1994-11-01 University Of Colorado Foundation, Inc. DNA sequences encoding proteins used to elicit and detect programmed cell death

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0760850A1 (en) * 1994-05-27 1997-03-12 Glaxo Group Limited P2x RECEPTORS (PURINOCEPTOR FAMILY)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0506032A1 (en) * 1991-03-28 1992-09-30 American Cyanamid Company Receptor purification method
US5360893A (en) * 1992-07-20 1994-11-01 University Of Colorado Foundation, Inc. DNA sequences encoding proteins used to elicit and detect programmed cell death

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BO X ET AL: "Solubilization and molecular size determination of the P2x purinoceptor from rat vas deferens.", J BIOL CHEM, SEP 5 1992, 267 (25) P17581-7, UNITED STATES *
OWENS, G.P. ET AL.;: "Identification of mRNAs associated with programmed cell death in immature thymocytes", MOLECULAR AND CELLULAR BIOLOGY, vol. 11, no. 8, pages 4177 - 4188 *
SIMON, JOSEPH ET AL: "Solubilization and molecular characterization of the P2X purinoceptor", BIOCHEM. SOC. TRANS., 1993, 200S *
VALERA S ET AL: "A new class of ligand-gated ion channel defined by P2x receptor for extracellular ATP.", NATURE, OCT 6 1994, 371 (6497) P516-9, ENGLAND *

Also Published As

Publication number Publication date
US5985603A (en) 1999-11-16
JPH10501122A (en) 1998-02-03
EP0760850A1 (en) 1997-03-12
US6194162B1 (en) 2001-02-27
WO1995033048A2 (en) 1995-12-07
AU2566595A (en) 1995-12-21

Similar Documents

Publication Publication Date Title
US5183657A (en) Antibodies for use in antilymphocyte antibody therapy
CA2140538A1 (en) Monoclonal antibodies that block ligand binding to the cd22 receptor in mature b cells
US4946788A (en) Purified immunoglobulin-related factor, novel monoclonal antibodies, hybridoma cell lines, processes and applications
EP0966300B1 (en) Treatment of rheumatoid arthritis with antibody anti ifn gamma
DE68925226T2 (en) Monoclonal antibodies
CA2124126A1 (en) Monoclonal antibodies and fv specific for cd2 antigen
EP0394946A3 (en) Human monoclonal antibody, and its production and use
WO1989009621A3 (en) Compounds for diagnosis and/or therapy of tumours
CA2203182A1 (en) Remedy for diseases caused by il-6 production
EP0378924A3 (en) Detection of neurological disease or dysfunction
EP0578774A4 (en) Monoclonal antibodies to stem cell factor receptors
CA2227548A1 (en) Human monoclonal antibody against hepatitis b virus surface antigen (hbvsag)
EP0955365A3 (en) Crystallization of M-CSF
CA2098295A1 (en) G protein-coupled glutamate receptors
US20060165694A1 (en) Polypeptides capable of forming antigen binding structures with specificity for the Rhesus D antigens, the DNA encoding them and the process for their preparation and use
Keegan et al. Superinduction of the murine B cell Fc epsilon RII by T helper cell clones. Role of IL-4.
Daëron et al. 2.4 G2, a monoclonal antibody to macrophage Fcγ receptors, reacts with murine T cell Fcγ receptors and IgG‐binding factors
WO1997000063A3 (en) Urocortin peptides
AU1046088A (en) Monoclonal antibody specific to neutrophils
RU2206614C2 (en) Monoclonal antibody raised to human cd23 and its using
CA2036814A1 (en) Monoclonal antibodies against tumor-associated antigens, a process for the preparation thereof and the use thereof
EP1186301A3 (en) Monoclonal antibodies that recognize flk-2 receptors and the isolation of primitive hematopoietic stem cell populations
CA2163868A1 (en) Monoclonal anti-idiotypic anti-ca125 antibodies and pharmaceutical compositions containing them
WO1996023884A3 (en) Human peroxisome proliferator activated receptors
AU556178B1 (en) Process and monoclonal antibodies to assay follicle- stimulating hormone

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995920076

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 08750134

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1995920076

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1995920076

Country of ref document: EP